Watch the interview here
Listen to the episode here
Hypertension remains one of the country’s most prevalent yet most uncontrolled conditions, costing the U.S. hundreds of billions of dollars each year. Despite the disease’s widespread presence, the fundamental approach to monitoring patients’ blood pressure hasn’t changed very much over the past century.
CoraVie Medical is seeking to address this problem by offering a continuous, effortless alternative to traditional cuff-based monitoring. In this MedCity Pivot podcast episode sponsored by CoraVie, CEO Aimee Garza and Dr. Michael Bloch, a hypertension specialist and clinical advisor for the startup, discuss why current monitoring methods often fail to capture meaningful blood pressure data due to fluctuations and white coat effects — and how these inaccurate measures can make clinical decision making difficult.
CoraVie’s implantable device automatically collects patients’ data, including crucial nighttime readings, which allows for more accurate diagnosis and tailored treatment. Both Garza and Bloch think the device could have an impact similar to that of continuous glucose monitors, noting that CoraVie’s product can empower patients in their daily lives and improve their medication management.